Finance

Beta
Lists
1789:TPE
ScinoPharm Taiwan Ltd
NT$20.75
+2.47%
(+0.50) 1D
Jun 9, 1:30:05 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 1789...
Open
NT$20.25
High
NT$21.40
Low
NT$20.25
Mkt. cap
16.41B
Avg. vol.
806.46K
Volume
1.63M
Dividend
1.40%
Quarterly dividend
NT$0.07
Ex-dividend date
Jul 2, 2026
P/E ratio
152.88
52-wk high
NT$29.10
52-wk low
NT$16.25
EPS
NT$0.14
Shares outstanding
790.74M
No. of employees
1K
Open
NT$20.25
High
NT$21.40
Low
NT$20.25
Mkt. cap
16.41B
Avg. vol.
806.46K
Volume
1.63M
Dividend
1.40%
Quarterly dividend
NT$0.07
Ex-dividend date
Jul 2, 2026
P/E ratio
152.88
52-wk high
NT$29.10
52-wk low
NT$16.25
EPS
NT$0.14
Shares outstanding
790.74M
No. of employees
1K
News stories
From sources across the web
About ScinoPharm Taiwan Ltd
CEO-
Employees1.01K
FoundedNov 11, 1997
Headquarters-
SectorPharmaceutical industry
Websitescinopharm.com
Previous reportsAll values in TWD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TWD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
747.52M
721.50M
1.01B
659.71M
Cost of goods sold
427.98M
505.66M
674.97M
438.17M
Cost of revenue
427.98M
505.66M
674.97M
438.17M
Research and development expenses
113.47M
121.40M
195.17M
85.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
125.79M
114.03M
128.12M
112.89M
Operating expense
239.27M
235.45M
325.04M
213.05M
Total operating expenses
667.26M
741.11M
1.00B
651.22M
Operating income
80.26M
-19.62M
8.03M
8.49M
Other non operating income
16.27M
-9.89M
19.92M
778.00K
EBT including unusual items
46.69M
19.18M
23.96M
19.32M
EBT excluding unusual items
46.46M
19.28M
21.96M
19.32M
Income tax expense
12.49M
3.73M
-17.32M
2.80M
Effective tax rate
26.75%
19.46%
-72.27%
14.47%
Other operating expenses
-
-
-
-
Net income
34.20M
15.45M
41.28M
16.53M
Net profit margin
4.58%
2.14%
4.10%
2.51%
Earnings per share
0.04
0.02
0.05
-
Interest and investment income
13.34M
37.62M
-
13.03M
Interest expense
-2.27M
-2.71M
-16.12M
-2.97M
Net interest expenses
11.07M
34.92M
-16.12M
10.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
202.53M
105.83M
134.08M
139.35M
Gain or loss from assets sale
-172.00K
100.00K
188.00K
21.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer